Search results
Results from the WOW.Com Content Network
Current Medicinal Chemistry is a peer-reviewed medical journal published by Bentham Science Publishers. The editor-in-chief is Atta-ur-Rahman, FRS (Kings College University of Cambridge Cambridge, UK). The journal covers developments in medicinal chemistry and rational drug design and publishes original research reports and review papers. [2]
Current Topics in Medicinal Chemistry is a biweekly peer-reviewed medical journal published by Bentham Science Publishers. It includes review articles on all aspects of medicinal chemistry, including drug design. The current editor-in-chief is Jia Zhou (University of Texas, Medical Branch).
With 79% of the Earth's surface covered by water, research into the chemistry of marine organisms is relatively unexplored and represents a vast resource for new medicines to combat major diseases such as cancer, AIDS or malaria. Research typically focuses on sessile organisms or slow moving animals because of their inherent need for chemical ...
Medicinal or pharmaceutical chemistry is a scientific discipline at the intersection of chemistry and pharmacy involved with designing and developing pharmaceutical drugs. Medicinal chemistry involves the identification, synthesis and development of new chemical entities suitable for therapeutic use.
Clinical pharmaceutical chemistry is a specialty branch of chemical sciences, which consists of medicinal chemistry with additional training in clinical aspects of translational sciences and medicine.
Bioprospecting (also known as biodiversity prospecting) is the exploration of natural sources for small molecules, macromolecules and biochemical and genetic information that could be developed into commercially valuable products for the agricultural, [2] [3] aquaculture, [4] [5] bioremediation, [4] [6] cosmetics, [7] [8] nanotechnology, [4] [9] or pharmaceutical [2] [10] industries.
The phrase "drug design" is similar to ligand design (i.e., design of a molecule that will bind tightly to its target). [6] Although design techniques for prediction of binding affinity are reasonably successful, there are many other properties, such as bioavailability, metabolic half-life, and side effects, that first must be optimized before a ligand can become a safe and effictive drug.
A 2013 review found the cost of developing a delivery system was only 10% of the cost of developing a new pharmaceutical. [16] A more recent study found the median cost of bringing a new drug to market was $985 million in 2020, but did not look at the cost of developing drug delivery systems. [17]